Drug Profile

DA 1241

Alternative Names: DA-1241

Latest Information Update: 28 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dong-A ST
Developer Dong-A ST; MetaVia
Class Antihyperglycaemics; Hepatoprotectants; Small molecules
Mechanism of Action GPR119 protein agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Non-alcoholic steatohepatitis
No development reported Type 2 diabetes mellitus

Most Recent Events

28 Aug 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO)
06 Aug 2025 Efficacy data from phase IIa trial in Non-alcoholic steatohepatitis released by MetaVia
04 Aug 2025 MetaVia and Syntekabio agree to co-develop DA 1241 for Non-alcoholic steatohepatitis and Type 2 diabetes mellitus

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com